Vaginal News and Research

RSS

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

Texas Health Presbyterian Hospital Dallas named Center of Excellence for gynecological surgery

Texas Health Presbyterian Hospital Dallas is the first hospital in Texas — and one of only three in the United States — to be named a Center of Excellence for gynecological surgery by the American Institute for Minimally Invasive Surgery.

9 Jul 2010

NOSCAR completes first NOTES transoral and transvaginal gallbladder removal in U.S. human trial

The Natural Orifice Surgery Consortium for Assessment and Research- (NOSCAR-), a joint effort of the American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), announces the completion of the first transoral and transvaginal cholecystectomies (gallbladder removal) using Natural Orifice Translumenal Endoscopic Surgery- (NOTES-) in a multicenter human trial in the United States.

From Evident Corporation - Life Sciences 8 Jul 2010

Columbia closes sale of progesterone related assets and 11.2M shares to Watson

Columbia Laboratories, Inc. announced today that it has closed the sale of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc.. Columbia's business now consists of its royalty and manufacturing revenues, potential milestone payments, its collaboration with Watson on the development of next-generation progesterone products, and its novel bioadhesive drug delivery technologies and other products.

6 Jul 2010

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.

2 Jul 2010

Study finds increased neonatal mortality among planned home births

About 1 in 200 women in the US delivers her baby at home, with approximately 75% of these low-risk, single-baby births planned in advance as home deliveries. In a study published online today by the American Journal of Obstetrics & Gynecology (AJOG), researchers from Maine Medical Center, Portland, Maine, analyzed the results of multiple studies from around the world.

1 Jul 2010

Simbionix, USF Health receive BIRD Grant for development of Laparoscopic Hysterectomy simulation module

Simbionix Ltd., a subsidiary of Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, and USF Health, an organization dedicated to creating a model of health care based on understanding the full spectrum of health, are proud to announce that together they received a BIRD (Binational Industrial Research and Development) Grant to support the development of a Laparoscopic Hysterectomy simulation module.

1 Jul 2010

Complication rates for vaginal and C-section deliveries can vary across hospitals

Complication rates for vaginal and C-section deliveries can vary widely from one hospital to the next according to a study released today by HealthGrades, the leading independent health care ratings organization.

30 Jun 2010

Seventh Annual HealthGrades Maternity Care in Hospitals Study ranks Good Samaritan in top 5%

Good Samaritan Hospital's maternity care is in the top 5 percent in the nation for the third year in a row according to a new study issued today by HealthGrades, Inc., the independent ratings organization. The Seventh Annual HealthGrades Maternity Care in Hospitals Study used state-government data to compare hospitals in terms of complication rates for vaginal and C-section deliveries as well as neonatal mortality.

30 Jun 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Much has been published of late, in medical journals as well as in the general media, concerning the national rise in both the Cesarean section and premature birth rates. While not directly connected, the two medical concerns have many interrelated variables. Nationally, the Cesarean section rate has risen to 32 percent of all births, while the rate of premature birth has climbed to just over 12 percent.

24 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

Synthetic sutures appear to cause less pain than natural "catgut" sutures in women who receive stitches after a vaginal birth, according to a new review of studies.

16 Jun 2010

Washington Post examines trial in Africa of long-acting vaginal ring for HIV prevention

"The first test of a long-acting vaginal ring loaded with an HIV-preventing drug has begun enrolling women in southern Africa," the Washington Post reports. The study, according to the newspaper, marks the 15th trial led by the nonprofit group, International Partnership for Microbicides, which "has helped lead the search for a discreet, woman-controlled means of protection" against the virus.

16 Jun 2010

Cytokine PharmaSciences completes misoprostol vaginal insert Phase II study

Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural labor, and reduce the rate of cesarean delivery.

16 Jun 2010

First clinical trial among African women to test vaginal ring that prevents HIV transmission

The nonprofit International Partnership for Microbicides today announced the initiation of the first trial among women in Africa testing a vaginal ring containing an antiretroviral drug that could one day be used to prevent HIV transmission during sex. The clinical trial, known as IPM 015, tests the safety and acceptability of an innovative approach that adapts a successful technology from the reproductive health field to give women around the world a tool to protect themselves from HIV infection.

9 Jun 2010

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

Columbia Laboratories, Inc. today announced it completed enrollment in the PREGNANT (PROCHIEVE Extending GestatioN A New Therapy) Study last week. This randomized, double-blind, placebo controlled Phase III clinical study is evaluating the safety and efficacy of PROCHIEVE® 8% (progesterone gel) to reduce the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.

8 Jun 2010

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Most Canadians would describe sexual desire as feelings of longing, craving, satisfying a sensuous appetite, or even the need for sensual indulgence. Today, the Society of Obstetricians and Gynaecologists of Canada wants to explain that desire is more than just a "feeling". The SOGC wants Canadian women to better understand the physical and psychosocial causes that may predispose to, precipitate or maintain a loss of desire.

5 Jun 2010

Delicate balance of microbes in vagina can vary between healthy women: New study

The delicate balance of microbes in the vagina can vary greatly between healthy women, according to a new study led by the University of Maryland School of Medicine's Institute for Genome Sciences. Researchers hope further study will lead to personalized reproductive medicine for women, allowing doctors to tailor each woman's treatment and health maintenance strategies to her individual microbial make-up.

4 Jun 2010

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Miconazole Nitrate Vaginal Cream and Suppository, a generic to Monistat® -1 Combination Pack. Perrigo expects to begin shipping immediately.

4 Jun 2010

Vaginal News and Research

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

Texas Health Presbyterian Hospital Dallas named Center of Excellence for gynecological surgery

NOSCAR completes first NOTES transoral and transvaginal gallbladder removal in U.S. human trial

Columbia closes sale of progesterone related assets and 11.2M shares to Watson

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Study finds increased neonatal mortality among planned home births

Simbionix, USF Health receive BIRD Grant for development of Laparoscopic Hysterectomy simulation module

Complication rates for vaginal and C-section deliveries can vary across hospitals

Seventh Annual HealthGrades Maternity Care in Hospitals Study ranks Good Samaritan in top 5%

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Florida obstetricians collaborate to lower premature and Cesarean birth rates

Research findings support the need to establish standards for DFSA care

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

Washington Post examines trial in Africa of long-acting vaginal ring for HIV prevention

Cytokine PharmaSciences completes misoprostol vaginal insert Phase II study

First clinical trial among African women to test vaginal ring that prevents HIV transmission

Columbia completes enrollment in PROCHIEVE 8% Phase III study to reduce preterm birth in short cervix women

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Delicate balance of microbes in vagina can vary between healthy women: New study

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News